Stryker, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Michael Matson from Needham reiterated a Buy rating on the stock and has a $454.00 price target.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Michael Matson has given his Buy rating due to a combination of factors that highlight Stryker’s solid operating momentum and growth outlook. The company closed 2025 with double‑digit organic revenue expansion and quarterly results that exceeded market expectations on both sales and earnings. In addition, management’s 2026 guidance for organic growth and EPS is aligned with or slightly above consensus, reinforcing confidence in Stryker’s ability to sustain its performance despite macro headwinds.
Stryker is also demonstrating resilience in the face of an anticipated $200M tariff headwind for 2026, with plans in place to fully neutralize this impact. The company is seeing strong demand across most of its portfolio, supported by higher procedure volumes, ongoing strength in hospital capital spending, and successful launches of new products. While gross margin was slightly pressured year over year, operating margin improved meaningfully, signaling effective cost management and operating leverage. Taken together, these dynamics underpin Matson’s view that Stryker remains well positioned for continued growth, justifying his Buy recommendation.
In another report released yesterday, BTIG also reiterated a Buy rating on the stock with a $412.00 price target.
Based on the recent corporate insider activity of 56 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SYK in relation to earlier this year.